Genotropin 16 IU KabiVial is more convenient than conventional administration systems for children on growth hormone therapy.
The use of a new device for reconstitution and storage of growth hormone (GH), Genotropin KabiVial, was studied in 20 children, aged 9-17 years, who had been receiving GH therapy using conventional administration systems. After 2 weeks of treatment, the convenience of the device and the patients' tolerance of it were assessed by the patients/families through a questionnaire. They were asked to compare the new device with the conventional method (standard vials and syringes). Most of the patients found the new device superior to the conventional method; they found that it was easier to reconstitute the GH and considered the multi-dose system and the smaller injection volume to be advantageous. Ninety per cent of the patients (p less than 0.001) expressed a preference for Genotropin 16 IU KabiVial for their future therapy.
Danielson
K
K
Department of Paediatrics, Karolinska Hospital, Stockholm, Sweden.
Neumeyer
L
L
Ritzén
M
M
D000293:Adolescent; D002648:Child; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy; D013006:Growth Hormone / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous / Q000295:instrumentation*; D008297:Male; D010349:Patient Compliance; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D013006:Growth Hormone